What is the latest POLYMED stock price?
The latest stored price for POLYMED is Rs 1,719.40 as of 2026-08-21.
gimli
POLYMED stock AI analysis
POLYMED Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
POLY MEDICURE LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available POLYMED price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,719.40
1W return
-3.74%
1M return
+1.39%
3M return
+10.89%
6M return
+36.92%
1Y return
-12.49%
Market cap
₹17,427.75 cr
PE
55.17
PB
5.53
ROE
+10.68%
ROCE
+13.76%
RSI
48.88
Turnover
₹16.66 cr
Why it can matter in screens
- Momentum: POLYMED is above 50DMA, above 200DMA; RSI is 48.88.
- Returns: 1D -2.84%, 1W -3.74%, 1M +1.39%, 3M +10.89%, 1Y -12.49%.
- Trend levels: 52W high ₹1,913.70, 52W low ₹1,300.00, off high -10.15%.
- Liquidity: latest turnover is ₹16.66 cr; volume vs 20D is +0.50%.
- Valuation/profitability: PE 55.17, PB 5.53, ROE +10.68%, ROCE +13.76%.
- Growth: 3Y sales CAGR +19.14%, 3Y profit CAGR +22.71%.
Quick Answers
Is POLYMED above its 50DMA and 200DMA?
POLYMED is above 50DMA, above 200DMA. The latest 50DMA is 1,684.03 and the latest 200DMA is 1,604.82.
What are POLYMED PE, ROE and ROCE?
POLYMED has PE 55.17, ROE +10.68%, and ROCE +13.76% in Gimli's latest available snapshot.
How has POLYMED performed recently?
POLYMED has returned +1.39% over 1 month, +10.89% over 3 months, and -12.49% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 459.75 cr | 149.49 cr | 88.12 cr | 8.49 |
| 2026-03-31 | 534.51 cr | 129.86 cr | 65.04 cr | 6.54 |
| 2025-12-31 | 493.66 cr | 132.33 cr | 70.93 cr | 7.00 |
| 2025-09-30 | 443.88 cr | 149.59 cr | 91.83 cr | 9.06 |
| 2025-06-30 | 403.21 cr | 149.15 cr | 93.08 cr | 9.19 |
| 2025-03-31 | 440.83 cr | 146.18 cr | 91.83 cr | 8.92 |
| 2024-12-31 | 424.21 cr | 137.92 cr | n/a | nan |
| 2024-09-30 | 420.02 cr | 142.18 cr | n/a | 9.01 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,875.26 cr | 561.28 cr | 331.29 cr | nan |
| 2025-03-31 | 1,669.83 cr | 547.69 cr | 338.56 cr | 34.13 |
| 2024-03-31 | 1,365.69 cr | 418.89 cr | 258.26 cr | 26.92 |
| 2023-03-31 | 1,108.66 cr | 303.20 cr | 179.28 cr | 18.69 |
| 2022-03-31 | 918.09 cr | 252.92 cr | 146.02 cr | 15.28 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 3,918.57 cr | 51.23 cr | 353.58 cr | 3,149.24 cr |
| 2025-03-31 | 3,192.45 cr | 8.70 cr | 180.25 cr | 2,765.66 cr |
| 2024-03-31 | 1,858.67 cr | 12.05 cr | 173.90 cr | 1,470.05 cr |
| 2023-03-31 | 1,577.21 cr | 7.06 cr | 149.02 cr | 1,241.63 cr |
| 2022-03-31 | 1,376.83 cr | 7.76 cr | 126.71 cr | 1,087.48 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 246.37 cr | -62.02 cr | n/a |
| 2025-03-31 | 233.05 cr | -97.98 cr | n/a |
| 2024-03-31 | 266.08 cr | -10.93 cr | n/a |
| 2023-03-31 | 191.05 cr | -48.22 cr | n/a |
| 2022-03-31 | 123.47 cr | -32.11 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +62.42% | +5.57% | +16.08% | +9.61% | +15.94% | +0.00% |
| 2026-03-31 | +62.42% | +5.91% | +15.59% | +8.84% | +16.08% | +0.00% |
| 2025-12-31 | +62.42% | +9.40% | +13.84% | +8.14% | +14.34% | +0.00% |
| 2025-09-30 | +62.42% | +9.77% | +13.54% | +8.04% | +14.27% | +0.00% |
| 2025-06-30 | +62.44% | +11.41% | +11.72% | +7.34% | +14.44% | +0.00% |
| 2025-03-31 | +62.44% | +11.46% | +11.96% | +7.16% | +14.15% | +0.00% |
| 2024-12-31 | +62.44% | +12.33% | +11.66% | +7.17% | +13.57% | +0.00% |
| 2024-09-30 | +62.56% | +11.87% | +12.33% | +7.35% | +13.24% | +0.00% |
| 2024-08-22 | +62.56% | +11.10% | +12.48% | +7.24% | +13.87% | +0.00% |
| 2024-06-30 | +66.03% | +9.91% | +9.35% | +6.29% | +14.72% | +0.00% |
| 2024-03-31 | +53.15% | +12.38% | +7.22% | +4.99% | +27.26% | +0.00% |
| 2023-12-31 | +53.16% | +14.10% | +5.45% | +4.18% | +27.29% | +0.00% |
| 2023-09-30 | +53.16% | +14.49% | +5.15% | +3.95% | +27.20% | +0.00% |
| 2023-06-30 | +53.31% | +15.61% | +4.25% | +3.27% | +26.83% | +0.00% |
| 2023-03-31 | +53.31% | +16.21% | +3.68% | +3.02% | +26.80% | +0.00% |
| 2022-12-31 | +53.33% | +16.33% | +3.38% | +3.01% | +26.96% | +0.00% |
| 2022-09-30 | +53.33% | +16.27% | +3.38% | +3.03% | +27.02% | +0.00% |
| 2022-06-30 | +53.34% | +0.00% | +18.84% | n/a | n/a | +0.00% |
| 2022-03-31 | +44.66% | +0.00% | +18.40% | n/a | n/a | n/a |
| 2021-12-31 | +44.76% | +0.00% | +17.12% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze POLY MEDICURE with valuation, momentum and industry peers
- Compare POLYMED with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare POLYMED with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.